Industry

Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)

BEIJING & NANJING, China–(BUSINESS WIRE)–Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (“NJCTTQ”) announced that NTB003 (formerly BCG009), a co-developed injectable drug candidate, has received the Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA). The approved indication is Thyroid Eye Disease (TED). About … [Read more…]

New Potential Treatment Strategy for Brain Metastases and Leptomeningeal Disease: HER3-DXd Shows Promising Results in the Phase II TUXEDO-3 Study for Patients With Limited Therapeutic Options

The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast and lung cancer and active brain metastases, and leptomeningeal disease from solid tumors. These results were presented as an oral presentation at the American Society of Clinical Oncology (ASCO) 2025 … [Read more…]

eClinical Solutions to Lead Industry Discussions on Modernizing Clinical Trials at DIA 2025 and Series of Company Events This Summer

Global eClinical Connect events kick off this week, leading up to annual ENGAGE conference in the fall, as company continues to build innovative avenues to empower life sciences leaders BOSTON–(BUSINESS WIRE)–eClinical Solutions LLC, a global provider of digital clinical software and services, today announced its participation in several June events, including the DIA 2025 Global … [Read more…]

The MolinaCares Accord and Molina Healthcare of Nevada Present Over $700,000 to the University of Nevada, Reno School of Medicine to Serve Under-Resourced Communities

RENO, Nev.–(BUSINESS WIRE)–The MolinaCares Accord (“MolinaCares”), in collaboration with Molina Healthcare of Nevada (“Molina”), today announced over $700,000 in grants to the University of Nevada, Reno School of Medicine (“UNR Med”) in support of six programs focused on enhancing access to care, especially in areas of Nevada with shortages of health professionals. Health workforce shortages … [Read more…]

Natera Announces Medicare Coverage for Signatera™ Genome

Broad coverage, inclusive of all previously covered Signatera indications AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its genome-based Signatera MRD assay is now covered by Medicare under LCD L38779. This coverage decision applies to Medicare beneficiaries with colorectal cancer, breast cancer, bladder cancer, ovarian … [Read more…]

Pacific Prime Saves Children with Congenital Heart Disease with Shanghai Rende Foundation Heart-to-Heart Fund

SHANGHAI–(BUSINESS WIRE)–Pacific Prime, a global health insurance intermediary group in international health insurance and employee benefits solutions, is proud to announce that two children with heart disease, financially assisted by Pacific Prime Group’s Shanghai office in China, successfully underwent surgeries in May 2025! The two children are a 3-year-old girl from Guizhou and an 11-year-old … [Read more…]

Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only

GENT, Belgium & MALVERN, Pa. & TOKYO–(BUSINESS WIRE)–#IVD–H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble … [Read more…]

U.S. FDA Approves NUBEQA® (darolutamide) to Treat Patients with Metastatic Castration-Sensitive Prostate Cancer

NUBEQA® is the first and only androgen receptor inhibitor (ARi) approved by the U.S. Food and Drug Administration (FDA) as a treatment for patients with metastatic castration-sensitive prostate cancer (mCSPC) with or without chemotherapy. Approval is based on positive results from the pivotal Phase III ARANOTE trial, which demonstrated NUBEQA plus androgen deprivation therapy (ADT) … [Read more…]

Personalis’ NeXT Personal® Predicts Cervical Cancer Recurrence Risk in New CALLA Phase 3 Study Analysis Presented at ASCO

FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate … [Read more…]

Cairns Health Commercially Releases Luna, an AI-powered Digital Care Companion for the Senior and Home Care Markets

Launching with multiple senior living and remote monitoring home care providers LOS ANGELES–(BUSINESS WIRE)–#AI–Cairns Health, a trailblazing healthcare technology company focused on radar-driven, AI-enabled monitoring and engagement solutions, is pleased to announce the commercial launch of Luna, the company’s patented intelligent ambient sensing and voice-based digital care companion, into multiple senior living communities and home … [Read more…]